CAR-T Cell Therapy Is Here To Stay – Forbes
Forbes |
CAR–T Cell Therapy Is Here To Stay
Forbes After decades of research and development, we're on the brink of a new era in the treatment of cancer, one where nearly every aspect—from the patient experience to the efficacy of treatments—may be upended. This treatment is known as chimeric antigen … FDA Advisory Committee Recommends Approval of CAR–T Cell Therapy and Two New Biosimilars |
